Answers are grounded in this paper and cite their sources.
Pityriasis rubra pilaris is a rare inflammatory dermatosis with off-label biologic use. We performed a systematic review and meta-analysis (PROSPERO CRD420261282142) of PubMed/MEDLINE and Embase (Ovid) up to 9 January 2026. Observational evidence was analysed at the therapeutic-line level. The primary outcome was complete/near-complete response (PASI100, IGA/PGA 0-1 or mapped equivalents); the secondary outcome was any response. Random-effects meta-analyses of proportions used a logit-scale generalized linear mixed model. Fourteen observational studies contributed 464 biologic therapeutic lines. The pooled any-response was 0.73 [95% Pityriasis rubra pilaris is a rare inflammatory dermatosis with off-label biologic use. We performed a systematic review and meta-analysis (PROSPERO CRD420261282142) of PubMed/MEDLINE and Embase (Ovid) up to 9 January 2026. Observational evidence was analysed at the therapeutic-line level. The primary outcome was complete/near-complete response (PASI100, IGA/PGA 0-1 or mapped equivalents); the secondary outcome was any response. Random-effects meta-analyses of proportions used a logit-scale generalized linear mixed model. Fourteen observational studies contributed 464 biologic therapeutic lines. The pooled any-response was 0.73 [95% confidence interval 0.64-0.81] and the pooled complete/near-complete response was 0.36 (0.23-0.52). In class-stratified analyses, complete/near-complete response was 0.27 for tumour necrosis factor inhibitors (N=200), 0.21 for interleukin-17 inhibitors (n=84) and 0.55 for interleukin-23 pathway inhibitors (n=135), with no significant between-class difference (p=0.057). In an exploratory analysis, complete/near-complete response rates were 0.71 (95% confidence interval 0.46-0.88; n=28) for interleukin-12/23 inhibitors and 0.58 (0.24-0.86; n=12) for interleukin-23p19 inhibitors; small sample sizes and overlapping confidence intervals preclude conclusions on target-specific differences. Adverse events or adverse event-related treatment discontinuations were reported in 12/183 courses with available safety information. Three prospective single-arm studies (n=35) reported PASI90 at week 24-28; pooled PASI90 was 0.26 (0.14-0.42). Overall, biologics were associated with frequent clinical improvement, whereas complete/near-complete clearance was less common; comparative inference across classes remains limited by observational designs and small denominators.
No takes yet. Share an insight, caveat, or question.
Tartaglia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: